Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pfizer/Agouron prinomastat

Executive Summary

Pfizer halts Phase III trials of the selective matrix metalloprotease inhibitor due to unmet primary efficacy objectives for the treatment of advanced hormone refractory prostate cancer and stage IV non-small cell lung cancer. Four Phase II studies in other indications are continuing. Prinomastat was developed by Agouron, which was acquired by Warner-Lambert in 1999. Following the consolidation of Warner-Lambert into Pfizer, Agouron's research division is now known as "Pfizer Global Research & Development, La Jolla Laboratories"

You may also be interested in...

ASCO In Brief

Gleevec filing for first-line CML: Novartis plans to file an NDA for Gleevec (imatinib) for first-line use in chronic myeloid leukemia patients in late June or early July, company says. In a 1,106-patient open-label Phase III trial presented at a plenary session of the American Society of Clinical Oncology, patients receiving 400 mg daily of Gleevec achieved higher major and complete cytogenetic responses (84% and 69%) compared to those receiving interferon-alfa and cytarabine arabinoside (30% and 11.5%, respectively). Complete hematologic response rates were 96% for the Gleevec arm and 67% for the IFN/Ara-C arm. Gleevec is currently indicated for second-line use in CML...

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts